ZSP1603 7.5 mg
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Overview
ZSP1603 7.5 mg is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
ZSP1603 7.5 mg clinical trials
Explore related
Medical disclaimer. This page summarizes research about ZSP1603 7.5 mg for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.